Vnitr Lek 2021, 67(1):37-40 | DOI: 10.36290/vnl.2021.005

Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient´s good and long-term adherence?

Vladimír Soška

Oddělení klinické biochemie, FN u sv. Anny v Brně

II. interní klinika LF MU a FN u sv. Anny v Brně

Treatment of dyslipidemia and hypertension is a key step for reducing the risk of atherosclerotic cardiovascular disease. Dyslipidemia and hypertension often occur in one patient at the same time, so both of these risk factors need to be addressed at the same time. It is better to start therapy before the patient is at high risk of a fatal cardiovascular event. To improve the patient's prognosis, it is important not only to achieve the target LDL-cholesterol value and the optimal blood pressure value, but it is also very important (and often more difficult) to maintain the patient's good and long-term adherence to established combination pharmacotherapy. For better adherence to long-term therapy also contributes reduction the number of tablets, which can be achieved through the use of a fixed combination of statins and antihypertensive agents.

Keywords: adherence, antihypertensive drugs, cardiovascular diseases, cardiovascular risk, dyslipidemia, hypertension, statins.

Published: March 2, 2021  Show citation